Summary
Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid metabolite, which regulates a broad range of physiological and pathophysiological processes. The signaling of S1P via its cell surface receptor S1PR1 has been identified to play an important role in carcinogenesis, cancer growth and survival, and tumor metastasis. In this study, we evaluated whether a monoclonal antibody against S1PR1 (S1PR1-antibody) could impose any effect on cell growth of human breast cancer SK-BR-3 and MDA-MB-231 cells. The S1PR1-antibody exhibited cytostatic effect against both cell lines at the concentration of 4000 ng/mL. Co-administration of 4000 ng/mL of the S1PR1-antibody not only potentiated the cytotoxicity of carboplatin towards the MDA-MB-231 cells but also increased the anti-proliferative effect of S1P towards the SK-BR-3 cells. Furthermore, we showed that co-administration of S1P did not sensitize the SK-BR-3 and MDA-MB-231 cells towards carboplatin.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Sphingosine-1-phosphate (S1P) is a common product of sphingolipid catabolism and an important bioactive sphingolipid metabolite. It exerts its biological functions both intracellularly and extracellularly to regulate various physiological and pathophysiological processes [1,2,3]. The intracellular function of S1P is not clearly understood. There is evidence showing that S1P acts as an intracellular messenger to regulate cell growth, invasion and apoptosis [4,5,6]. However, the extracellular function of S1P has been well studied, and S1P employs an “inside-out” signaling mode for its biological functions [7,8,9,10]. Briefly, S1P is first synthesized inside cells, and then transported out of the cells to interact with a family of five G protein-coupled sphingosine-1-phosphate receptors (S1PR1–5) [9, 10]. Receptors S1PR1–3 are relatively ubiquitously expressed with S1PR1 possessing the highest expression level; whereas S1PR4 is mainly expressed in lymphoid tissues and blood cells and S1PR5 is expressed in brain, skin and natural killer cells [11,12,13]. S1P promotes cell proliferation and survival, inhibits cell apoptosis, and enhances angiogenesis via binding S1PR1 and S1PR3 [9, 10, 14, 15]. However, upon biding S1PR2, S1P inhibits cell proliferation and survival and induces cell apoptosis [9, 10, 16, 17].
Extensive studies have concluded that the S1P-S1PR signaling axis plays an important role in cancer development and progression [9, 10]. Sphingosine kinase 1 (SK1), which is a cytosolic enzyme catalyzing the synthesis of S1P, is upregulated in various types of cancer [18,19,20]. It has also been shown that overexpression of SK1 promotes cancer metastasis and is responsible for the poor prognosis of breast cancer [21]. SK1 is required for epidermal growth factor (EGF)-directed motility and acts as a key regulator of breast cancer progression [22]. These observations implicate that SK1 is a valid anticancer therapeutic target [23, 24]. Furthermore, antagonization of S1PR1 by FTY720, a potent immunomodulator, caused internalization and desensitization of S1PR1 and inhibited tumor-associated angiogenesis [25]. Thus, downregulation of the S1P-S1PR1 signaling pathway would likely be an effective option to impede cancer development and progression.
In order to evaluate whether the expression status of S1PR1–3 affects human breast cancer patient’s survival, we extracted the Kaplan-Meier plots of survival probability versus mRNA expression level for S1PR1–3 from patients’ data deposited at The Human Protein Atlas (HPA) database (https://www.proteinatlas.org/). As shown in Fig. 1, the mRNA expression status of S1PR1 does not have any significant effect on breast cancer patients’ survival; however, both S1PR2 and S1PR3 are favorable prognostic factors for breast cancer patients’ survival. Therefore, in the current study, we decided to undertake a preclinical evaluation on whether blocking receptor S1PR1 using a monoclonal antibody (S1PR1-antibody), while leaving receptors S1PR2 and S1PR3 unblocked, would exhibit any antitumor effect against two highly invasive human breast cancer cell lines, HER2 subtype SK-BR-3 cell line and triple-negative subtype MDA-MB-231 cell line.
Materials and methods
Materials
All chemicals including sphingosine-1-phosphate (S1P), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and carboplatin were purchased from Sigma-Aldrich Canada (Oakville, ON, Canada). The MTT stock solution was prepared by dissolving MTT powder in phosphate buffered saline (1X PBS, pH 7.4) with the final concentration of 5 mg/mL. Monoclonal antibody against human S1PR1 (S1PR1-antibody) was purchased from Abcam Inc. (Toronto, ON, Canada). Human breast cancer cell lines SK-BR-3 and MDA-MB-231 were purchased from the American Type Culture Collection (ATCC) (Manassas, VA, USA). The cell culture media for cell lines SK-BR-3 and MDA-MB-231 were purchased from Cedarlane Canada (Burlington, ON, Canada). CellTox™ Green Cytotoxicity Assay was purchased from Promega North America (Madison, WI, USA).
Cell culture
Human breast cancer cell lines SK-BR-3 and MDA-MB-231 were cultured in T-75 cell culture flasks under a humidified atmosphere at 37 °C. The SK-BR-3 cells were cultured in McCoy’s 5A Modified Medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin under 5% CO2; and the MDA-MB-231 cells were cultured in Leibovitz’s L-15 Medium supplemented with 10% FBS and 1% penicillin under 0% CO2. Cell culture media were changed every 2–3 days.
Cell viability assay
Cell viability was determined using the MTT assay. Both SK-BR-3 and MDA-MB-231 cells were plated in 96-well plates at 8000 cells per well with the final cell culture volume of 100 μL and allowed to grow to 70–80% confluence before being subjected to different treatments. The treatment time was 48 h and 72 h, respectively. At the end of each treatment, the cell culture media were discarded and replaced with 100 μL MTT solution (prepared by adding 1 mL MTT stock solution to 9 mL cell culture media). The cell culture plates were then incubated at 37 °C for 3 h. After incubation, the MTT solution was discarded and 100 μL of dimethyl sulfoxide (DMSO) was added to each well to dissolve the MTT formazan. Subsequently, the cell culture plates were wrapped up in aluminum foil and shook on an orbital shaker at room temperature for 10 min. The absorbance was recorded at 570 nm on a BioTek® microplate reader (BioTek Canada, Winooski, VT, USA). The cell viability was calculated using Eq. 1.
For the effect of the S1PR1-antibody on cell viability of SK-BR-3 and MDA-MB-231 cells, the concentration of the S1PR1-antibody was ranging from 16 ng/mL to 4000 ng/mL. 1X PBS buffer (pH 7.4), in which the S1PR1-antibody was dissolved, was used as the vehicle control. For the effect of the combination of the S1PR1-antibody and carboplatin on cell viability of SK-BR-3 and MDA-MB-231 cells, the S1PR1-antibody concentration was 4000 ng/mL and the carboplatin concentration was 4 μM towards the SK-BR-3 cells and 67.5 μM towards the MDA-MB-231 cells. PBS buffer (1X, pH 7.4) was used as the vehicle control. For the effect of the combination of the S1PR1-antibody and S1P on cell viability of SK-BR-3 and MDA-MB-231 cells, the concentration of the S1PR1-antibody was 4000 ng/mL and the concentration of S1P was 10 μM/mL. Methanol with 120 mg/mL PEG 3350 (polyethylene glycol 3350), in which S1P was dissolved, was used as the vehicle control. For the effect of the combination of S1P and carboplatin on cell viability of SK-BR-3 and MDA-MB-231 cells, the S1P concentration was at 1 μM and 10 μM, respectively. The carboplatin concentration was ranging from 4 μM to 540 μM for the SK-BR-3 cells and from 67.5 μM to 1080 μM for the MDA-MB-231 cells, respectively. Methanol with 120 mg/mL PEG 3350 was used as the vehicle control.
Cytotoxicity assay
The SK-BR-3 and MDA-MB-231 cells were plated in 96-well plates at 8000 cells per well with the final culture volume of 100 μL and allowed to grow to 70–80% confluence before being treated with S1PR1-antibody for 48 h and 72 h, respectively. The concentration of S1PR1-antibody was ranging from 16 ng/mL to 4000 ng/mL, with 1X PBS buffer (pH 7.4), in which S1PR1-antibody was dissolved, as the negative control. The cytotoxicity was measured using the CellTox™ Green Cytotoxicity Assay from Promega and calculated using Eq. 2.
Statistical analysis
The statistical analysis of the data was carried out by two-way ANOVA with Tukey’s post hoc analysis using GraphPad Prism 6 (GraphPad Software, La Jolla, CA, USA). The significance was set at p ≤ 0.05 (*, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; and ****, p ≤ 0.0001).
Results and discussion
S1PR1-antibody exhibited cytostatic effect
The promoting effect of S1P on cell proliferation, migration and metastasis of different types of cancer is mainly through S1PR1 [9, 10, 26,27,28]. S1PR1 antagonists were shown to be able to inhibit tumor angiogenesis in vivo and enhance the therapeutic efficacy of doxorubicin [29, 30]. Taking in consideration that S1PR2 and S1PR3 are favorable prognostic factors for human breast cancer (Fig. 1), we examined whether blocking S1PR1 with a monoclonal S1PR1-antibody and allowing endogenous S1P to interact selectively with S1PR2 and S1PR3 would inhibit the growth of the highly invasive human breast cancer SK-BR-3 (HER2 subtype) and MDA-MB-231 (triple-negative subtype) cells. We first assessed the effect of the S1PR1-antibody on cell viability of SK-BR-3 and MDA-MB-231 cells using the MTT assay. As shown in Fig. 2a, SK-BR-3 cells exhibited a dose-dependent and time-dependent response towards S1PR1-antibody; however, the response was relatively mild. The maximum effect of about 10% reduction in cell viability was achieved at the treatment of 4000 ng/mL S1PR1-antibody for 72 h. For the MDA-MB-231 cells, the S1PR1-antibody promoted cell growth at low concentrations (16–500 ng/mL) and inhibited cell growth at high concentrations (1000–4000 ng/mL) (Fig. 2b). The maximum promoting effect of cell growth (~ 10% increase in cell viability) was at treatment of 125 ng/mL S1PR1-antibody for 72 h, whereas the maximum inhibiting effect on cell growth (~27% decrease in cell viability) was at treatment of 4000 ng/mL S1PR1-antibody for 72 h. To further understand whether the inhibition of cell growth by the S1PR1-antibody was due to cytostatic or cytotoxic effect, we measured the cytotoxicity of the S1PR1-antibody towards the SK-BR-3 and MDA-MB-231 cells using the CytoTox™ Green Cytotoxicity Assay under the same experimental condition. The S1PR1-antibody did not cause any cytotoxic effect towards either SK-BR-3 cells or MDA-MB-231 cells, except a small 10% cytotoxicity towards the MDA-MB-231 cells at treatment of 4000 ng/mL S1PR1-antibody for 72 h (Fig. 2c, d). We speculated that this small cytotoxicity might be caused by the differences of S1PR1 expression and internalization between the two cell lines. However, we could not completely rule out the possibility of that a different antigen possesses a fragment of sequence highly homologous to the epitope used in producing the S1PR1-antibody and binds S1PR1-antibody, even with much weaker binding affinity, in the MDA-MB-231 cells. In summary, we conclude that the inhibitory function of the S1PR1-antibody on cell growth of the SK-BR-3 and MDA-MB-231 cells is likely through cytostatic effect. Further studies are warranted to identify whether blocking S1PR1 by the S1PR1-antibody would change endogenous S1P synthesis and/or affect S1P-S1PR2 and S1P-S1PR3 signaling in human breast cancer cells.
S1PR1-antibody potentiated the cytotoxicity of carboplatin towards MDA-MB-231 cells
Platinum-based chemotherapy drugs are a family of alkylating agents widely used to treat different types of cancer, such as small cell lung cancer, head and neck cancer and ovarian cancer. However, breast cancer does not respond well towards platinum-based drugs; and carboplatin, usually in combination with other chemotherapy drugs, is the only platinum-based drug approved to treat advanced-stage breast cancer [31, 32]. Since antagonization of S1PR1 has been observed to enhance the efficacy of doxorubicin [25, 30], we decided to evaluate whether the S1PR1-antibody could potentiate the cytotoxic effect of carboplatin towards SK-BR-3 and MDA-MB-231 cells. The IC50 of carboplatin was determined to be 80.0 μM (48 h) and 30.6 μM (72 h) against the SK-BR-3 cells and 834 μM (48 h) and 294 μM (72 h) against the MDA-MB-231 cells, respectively (supplementary Fig. S1). It is extremely high compared to the reported IC50 of carboplatin towards several cell lines derived from ovarian cancer patients, which is around 1 μM for pre-chemotherapy cell lines and 5 μM for post-chemotherapy cell lines [33]. This implicates that carboplatin might not be a first choice for treating HER2 or triple-negative subtype breast cancer, although it is approved for advanced-stage breast cancer.
In order to get a glimpse on whether the S1PR1-antibody could improve the response of SK-BR-3 and MDA-MB-231 cells towards carboplatin, we evaluated the effect of carboplatin in combination of 4000 ng/mL of S1PR1-antibody on the cell viability of SK-BR-3 and MDA-MB-231 cells. For both cell lines, we chose a concentration of carboplatin significantly lower than the IC50 (4 μM for SK-Br-3 and 68 μM for MDA-MB-231), which does not impose any cytotoxicity to the cells. The reason for this type of selection is to ensure that this research would lead to further in vivo and even clinically meaningful studies if the S1PR1-antibody indeed sensitized the breast cancer cells to carboplatin, as the IC50 of carboplatin was only around 1 μM towards patient-derived ovarian cancer cell lines [33]. As shown in Fig. 3, co-administration of S1PR1-antibody did not sensitize the SK-BR-3 cells towards carboplatin treatment. For MDA-MB-231 cells, the co-administration of S1PR1-antibody and carboplatin decreased the cell viability by more than 35% compared to carboplatin alone (p ≤ 0.0001) and almost 10% compared to S1PR1-antibody alone (p ≤ 0.01) at 48 h of treatment (Fig. 3). This implicated that S1PR1-antibody enhanced the cytotoxic effect of carboplatin. However, at 72 h of treatment, we did not observe any significant difference in cell viability between S1PR1-antibody alone and its combination with carboplatin. We speculated that this was due to the cytostatic effect of the S1PR1-antibody, as carboplatin targets fast-growing cells and prolonged treatment with the S1PR1-antibody made the MDA-MB-231 cells insensitive towards carboplatin. Further studies are warranted to identify the optimal conditions, such as S1PR1-antibody and carboplatin concentrations and the sequential order of the administration, to achieve the best efficacy (i.e. synergistic/additive effect) of the cytostatic effect of S1PR1-antibody and cytotoxic effect of carboplatin. In addition, we have already imitated a study to evaluate whether the S1PR1-antibody could exhibit any synergistic/additive effect with other chemotherapy drugs, such as docetaxel, doxorubicin and lapatinib, against both HER2 subtype and triple-negative subtype human breast cancer cell lines.
S1PR1-antibody enhanced the effect of S1P towards SK-BR-3 cells
In our previous studies, we showed that S1P selectively induced cell apoptosis in breast cancer MCF7 cells and exhibited synergistic effect with chemotherapy drugs towards breast cancer MCF7 and MDA-MB-361 cells at a concentration higher than 1 μM, especially at 10 μM [34, 35]. Therefore, we decided to evaluate whether there could be any synergistic/additive effect between S1PR1-antibody (concentration: 4000 ng/mL) and S1P (concentration: 10 μM). For the SK-BR-3 cells, S1P did not exhibit any significant effect on cell viability compared to the vehicle control at either 48 h or 72 h treatment; however, co-administration of S1PR1-antibody decreased the cell viability by almost 20% (p ≤ 0.0001) at 48 h of treatment (Fig. 4). At 72 h of treatment, the co-administration of S1PR1-antibody reduced the cell viability by approximately 10%; however, this decrease is not statistically significant (Fig. 4). For the MDA-MB-231 cells, S1P induced about 20–25% reduction in cell viability compared to the vehicle control at 48 h or 72 h of treatment; however, co-administration of S1PR1-antibody did not further reduce the cell viability at either treatment time (Fig. 4). This study implicated that S1PR1-antibody was able to enhance the effect of S1P against the SK-BR-3 cells. A study has been initiated to understand how the S1PR1-antibody affects the intracellular function of S1P, as our studies suggested that the selective cytotoxic effect of S1P towards human breast cancer cells at concentrations higher than 1 μM is highly likely through its intracellular function (data not published).
S1P did not elevate the cytotoxicity of carboplatin
S1P has been shown to potentiate the cytotoxic effects of docetaxel, doxorubicin and cyclophosphamide towards human breast cancer cells at high concentrations (≥ 1 μM) [34, 35]. In the current study, we also evaluated whether S1P (concentration: 1 μM and 10 μM) could improve the sensitivity of the SK-BR-3 and MDA-MB-231 cells to carboplatin, as neither type of cells is responding well to carboplatin treatment (supplementary Fig. S1) in spite of that carboplatin has been approved for advanced-stage breast cancer. Neither 1 μM nor 10 μM concentration of S1P was able to improve the response of the SK-BR-3 and MDA-MB-231 cells to carboplatin treatment (Fig. 5). However, S1P (concentration: 10 μM) decreased the cell viability of the SK-BR-3 and MDA-MB-231 cells by approximately 15 and 30%, respectively at both 48 h and 72 h treatments. For both cell lines, when carboplatin concentration was less than the IC50 values, the effect of the co-administration of S1P (concentration: 10 μM) and carboplatin on cell viability was dominated by S1P. Whereas the carboplatin concentration was increased higher than the IC50 values, the effect of the co-administration of S1P (concentration: 10 μM) and carboplatin on cell viability was controlled by carboplatin. Therefore, in contrary to our previous studies that S1P can increase the cytotoxic activities of docetaxel, doxorubicin and cyclophosphamide, co-administration of high concentrations of S1P does not improve the cytotoxic activity of carboplatin.
Conclusion
In this study, we showed that the S1PR1-antibody exhibited cytostatic effect towards both HER2 subtype SK-BR-3 cell line and triple-negative subtype MDA-MB-231 cell line. Co-administration of 4000 ng/mL of the S1PR1-antibody not only potentiated the cytotoxicity of carboplatin towards cell line MDA-MB-231 but also increased the anti-proliferative effect of S1P towards cell line SK-BR-3. Furthermore, co-administration of S1P did not improve the response of the SK-BR-3 and MDA-MB-231 cells towards carboplatin treatment.
References
Pyne NJ, El Buri A, Adams DR, Pyne S (2017) Sphingosine 1-phosphate and cancer. Adv Biol Regul 68:97–106. https://doi.org/10.1016/j.jbior.2017.09.006
Maceyka M, Spiegel S (2014) Sphingolipid metabolites in inflammatory disease. Nature 510:58–67. https://doi.org/10.1038/nature13475
Weske S, Vaidya M, Reese A, von Wnuck Lipinski K, Keul P, Bayer JK, Fischer JW, Flögel U, Nelsen J, Epple M, Scatena M, Schwedhelm E, Dörr M, Völzke H, Moritz E, Hannemann A, Rauch BH, Gräler MH, Heusch G, Levkau B (2018) Targeting sphingosine-1-phosphate lyase as an anabolic therapy for bone loss. Nat Med 24:667–678. https://doi.org/10.1038/s41591-018-0005-y
Igarashi N, Okada T, Hayashi S, Fujita T, Jahangeer S, Nakamura S (2003) Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. J Biol Chem 278:46832–46839. https://doi.org/10.1074/jbc.M306577200
Ohotski J, Rosen H, Bittman R, Pyne S, Pyne NJ (2014) Sphingosine kinase 2 prevents the nuclear translocation of sphingosine 1-phosphate receptor-2 and tyrosine 416 phosphorylated c-Src and increases estrogen receptor negative MDA-MB-231 breast cancer cell growth: The role of sphingosine 1-phosphate receptor. Cell Signal 26:1040–1047. https://doi.org/10.1016/j.cellsig.2014.01.023
Pébay A, Toutant M, Prémont J, Calvo CF, Venance L, Cordier J, Glowinski J, Tencé M (2001) Sphingosine-1-phosphate induces proliferation of astrocytes: regulation by intracellular signalling cascades. Eur J Neurosci 13:2067–2076. https://doi.org/10.1046/j.0953-816x.2001.01585.x
Takabe K, Paugh SW, Milstien S, Spiegel S (2008) “Inside-out” signaling of Sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 60:181–195. https://doi.org/10.1124/pr.107.07113
Pyne NJ, McNaughton M, Boomkamp S, MacRitchie N, Evangelisti C, Martelli AM, Jiang H-R, Ubhi S, Pyne S (2016) Role of sphingosine 1-phosphate receptors, sphingosine kinases and sphingosine in cancer and inflammation. Adv Biol Regul 60:151–159. https://doi.org/10.1016/j.jbior.2015.09.001
Strub GM, Maceyka M, Hait NC, Milstien S, Spiegel S (2010) Extracellular and intracellular actions of sphingosine-1-phosphate. Adv Exp Med Biol 688:141–155
Pyne NJ, Pyne S (2010) Sphingosine 1-phosphate and cancer. Nat Rev Cancer 10:489–503. https://doi.org/10.1038/nrc2875
Olesch C, Ringel C, Brüne B, Weigert A (2017) Beyond immune cell migration: the emerging role of the Sphingosine-1-phosphate receptor S1PR4 as a modulator of innate immune cell activation. Mediat Inflamm 2017:6059203. https://doi.org/10.1155/2017/6059203
Rivera J, Proia RL, Olivera A (2008) The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol 8:753–763. https://doi.org/10.1038/nri2400
Di Pardo A, Castaldo S, Amico E, Pepe G, Marracino F, Capocci L, Giovannelli A, Madonna M, van Bergeijk J, Buttari F, van der Kam E, Maglione V (2018) Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington’s disease. Hum Mol Genet. https://doi.org/10.1093/hmg/ddy153
Sassoli C, Pierucci F, Tani A, Frati A, Chellini F, Matteini F, Vestri A, Anderloni G, Nosi D, Zecchi-Orlandini S, Meacci E (2018) Sphingosine 1-phosphate receptor 1 is required for MMP-2 function in bone marrow mesenchymal stromal cells: implications for cytoskeleton assembly and proliferation. Stem Cells Int 2018:5034679. https://doi.org/10.1155/2018/5034679
Hirata N, Yamada S, Shoda T, Kurihara M, Sekino Y, Kanda Y (2014) Sphingosine-1-phosphate promotes expansion of cancer stem cells via S1PR3 by a ligand-independent Notch activation. Nat Commun 5:4806. https://doi.org/10.1038/ncomms5806
Takuwa N, Du W, Kaneko E, Okamoto Y, Yoshioka K, Takuwa Y (2011) Tumor-suppressive sphingosine-1-phosphate receptor-2 counteracting tumor-promoting sphingosine-1-phosphate receptor-1 and sphingosine kinase 1 - Jekyll Hidden behind Hyde. Am J Cancer Res 1:460–481
Arikawa K, Takuwa N, Yamaguchi H, Sugimoto N, Kitayama J, Nagawa H, Takehara K, Takuwa Y (2003) Ligand-dependent inhibition of B16 melanoma cell migration and invasion via endogenous S1P 2 G protein-coupled receptor. J Biol Chem 278:32841–32851. https://doi.org/10.1074/jbc.M305024200
Madhunapantula SV, Hengst J, Gowda R, Fox TE, Yun JK, Robertson GP (2012) Targeting sphingosine kinase-1 to inhibit melanoma. Pigment Cell Melanoma Res 25:259–274. https://doi.org/10.1111/j.1755-148X.2012.00970.x
Marfe G, Di Stefano C, Gambacurta A, Ottone T, Martini V, Abruzzese E, Mologni L, Sinibaldi-Salimei P, de Fabritis P, Gambacorti-Passerini C, Amadori S, Birge RB (2011) Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells. Exp Hematol 39:653–665.e6. https://doi.org/10.1016/j.exphem.2011.02.013
Li W, Yu C-P, Xia J-t, Zhang L, Weng G-X, Zheng H-q, Kong Q-l, Hu L-j, Zeng M-S, Zeng Y-x, Li M, Li J, Song L-B (2009) Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res 15:1393–1399. https://doi.org/10.1158/1078-0432.CCR-08-1158
Zhu Y-J, You H, Tan J-X, Li F, Qiu Z, Li H-Z, Huang H-Y, Zheng K, Ren G-S (2017) Overexpression of sphingosine kinase 1 is predictive of poor prognosis in human breast cancer. Oncol Lett 14:63–72. https://doi.org/10.3892/ol.2017.6134
Long JS, Edwards J, Watson C, Tovey S, Mair KM, Schiff R, Natarajan V, Pyne NJ, Pyne S (2010) Sphingosine kinase 1 induces tolerance to human epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor-positive breast cancer cells. Mol Cell Biol 30:3827–3841. https://doi.org/10.1128/MCB.01133-09
Gao Y, Gao F, Chen K, Tian M, Zhao D (2015) Sphingosine kinase 1 as an anticancer therapeutic target. Drug Des Devel Ther 9:3239–3245. https://doi.org/10.2147/DDDT.S83288
Ogretmen B (2018) Sphingolipid metabolism in cancer signalling and therapy. Nat Rev Cancer 18:33–50. https://doi.org/10.1038/nrc.2017.96
LaMontagne K, Littiewood-Evans A, Schnell C, O’Reilly T, Wyder L, Sanchez T, Probst B, Butler J, Wood A, Liau G, Billy E, Theuer A, Hla T, Wood J (2006) Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res 66:221–231. https://doi.org/10.1158/0008-5472.CAN-05-2001
Xu X, Huang C, Zhang Y, Chen L, Cheng H, Wang J (2016) S1PR1 mediates anti-apoptotic/pro-proliferative processes in human acute myeloid leukemia cells. Mol Med Rep 14:3369–3375. https://doi.org/10.3892/mmr.2016.5629
Cheng N, Wang G-H (2016) miR-133b, a microRNA targeting S1PR1, suppresses nasopharyngeal carcinoma cell proliferation. Exp Ther Med 11:1469–1474. https://doi.org/10.3892/etm.2016.3043
Go H, Kim P-J, Jeon YK, Cho YM, Kim K, Park B-H, Ku JY (2015) Sphingosine-1-phosphate receptor 1 (S1PR1) expression in non-muscle invasive urothelial carcinoma: association with poor clinical outcome and potential therapeutic target. Eur J Cancer 51:1937–1945. https://doi.org/10.1016/j.ejca.2015.07.021
Fujii Y, Ueda Y, Ohtake H, Ono N, Takayama T, Nakazawa K, Igarashi Y, Goitsuka R (2012) Blocking S1P interaction with S1P1receptor by a novel competitive S1P1-selective antagonist inhibits angiogenesis. Biochem Biophys Res Commun 419:754–760. https://doi.org/10.1016/j.bbrc.2012.02.096
Katsuta E, Yan L, Nagahashi M, Raza A, Sturgill JL, Lyon DE, Rashid OM, Hait NC, Takabe K (2017) Doxorubicin effect is enhanced by sphingosine-1-phosphate signaling antagonist in breast cancer. J Surg Res 219:202–213. https://doi.org/10.1016/j.jss.2017.05.101
Eckstein N (2011) Platinum resistance in breast and ovarian cancer cell lines. J Exp Clin Cancer Res 30:91. https://doi.org/10.1186/1756-9966-30-91
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750–2767. https://doi.org/10.1172/JCI45014
Létourneau IJ, Quinn MCJ, Wang L-L, Portelance L, Caceres KY, Cyr L, Delvoye N, Meunier L, de Ladurantaye M, Shen Z, Arcand SL, Tonin PN, Provencher DM, Mes-Masson A-M (2012) Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer. BMC Cancer 12:379. https://doi.org/10.1186/1471-2407-12-379
Ling B, Chen L, Alcorn J, Ma B, Yang J (2011) Sphingosine-1-phosphate: a potential therapeutic agent against human breast cancer. Investig New Drugs 29:396–399. https://doi.org/10.1007/s10637-009-9375-9
Sultan A, Ling B, Zhang H, Ma B, Michel D, Alcorn J, Yang J (2013) Synergistic effect between sphingosine-1-phosphate and chemotherapy drugs against human brainmetastasized breast cancer MDA-MB-361 cells. J Cancer 4:315–319. https://doi.org/10.7150/jca.5956
Acknowledgements
We would like to thank Drs. Meena K. Sakharkar and Jane Alcorn for valuable suggestions.
Funding
The work was supported in part by a President-NSERC grant from the University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Author information
Authors and Affiliations
Contributions
This research work was designed by Jian Yang and carried out by Shujun Xiao.
Corresponding author
Ethics declarations
Conflict of interest
Shujun Xiao declares that she has no conflict of interest. Jian Yang declares that he has no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Electronic supplementary material
ESM 1
(DOCX 117 kb)
Rights and permissions
About this article
Cite this article
Xiao, S., Yang, J. Preclinical study of the antitumor effect of sphingosine-1-phosphate receptor 1 antibody (S1PR1-antibody) against human breast cancer cells. Invest New Drugs 37, 57–64 (2019). https://doi.org/10.1007/s10637-018-0618-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-018-0618-5